These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 10805430)
1. Development of a specific immunoadsorbent containing immobilized synthetic peptide of acetylcholine receptor for treatment of myasthenia gravis. 1993. Nakaji S; Oka K; Tanihara M; Takakura K; Takamori M Ther Apher; 2000 Apr; 4(2):124-6. PubMed ID: 10805430 [No Abstract] [Full Text] [Related]
2. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor. Takamori M; Maruta T Ther Apher; 2001 Oct; 5(5):340-50. PubMed ID: 11778918 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic immunoadsorption of acetylcholine receptor antibodies in myasthenia gravis. Sato T; Ishigaki Y; Komiya T; Tsuda H Ann N Y Acad Sci; 1988; 540():554-6. PubMed ID: 3061349 [No Abstract] [Full Text] [Related]
4. Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis. Zisimopoulou P; Lagoumintzis G; Kostelidou K; Bitzopoulou K; Kordas G; Trakas N; Poulas K; Tzartos SJ J Neuroimmunol; 2008 Sep; 201-202():95-103. PubMed ID: 18667243 [TBL] [Abstract][Full Text] [Related]
5. [Plasmapheresis in patients with myasthenia gravis]. Konishi T Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364 [TBL] [Abstract][Full Text] [Related]
6. Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis. Takamori M; Ide Y Transfus Sci; 1996 Sep; 17(3):445-53. PubMed ID: 10163553 [TBL] [Abstract][Full Text] [Related]
7. Anti-MuSK positivity on plasmapheresis liquid in a double seronegative myasthenia gravis patient. Renard D; Candon S; Jacob M; Trusson R; Reboul P Acta Neurol Belg; 2018 Mar; 118(1):119-120. PubMed ID: 28608313 [No Abstract] [Full Text] [Related]
8. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975. Lindstrom JM; Seybold ME; Lennon VA; Whittingham S; Duane DD Neurology; 1998 Oct; 51(4):933 and 6 pages following. PubMed ID: 9781505 [No Abstract] [Full Text] [Related]
9. Removal Characteristics of Immunoadsorption with the Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis. Ohkubo A; Okado T; Sakurasawa T; Maeda T; Itagaki A; Yamamoto H; Miyamoto S; Seshima H; Kurashima N; Mori T; Iimori S; Sohara E; Rai T; Uchida S; Naito S Ther Apher Dial; 2019 Jun; 23(3):271-278. PubMed ID: 31025833 [TBL] [Abstract][Full Text] [Related]
10. Current trends in the management of myasthenia gravis: plasmapheresis and immunosuppressive therapy. Pollard JD; Basten A; Hassall JE; Kronenberg H; Cobcroft R; Dawkins R Aust N Z J Med; 1980 Apr; 10(2):212-7. PubMed ID: 6930213 [TBL] [Abstract][Full Text] [Related]
11. [Immunoadsorption--a new treatment of myasthenia gravis]. Berning T; Krummenerl T; Glaser J; Paulus H; van Husen N Med Klin (Munich); 1988 Feb; 83(4):125-8. PubMed ID: 3285161 [No Abstract] [Full Text] [Related]
12. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395 [TBL] [Abstract][Full Text] [Related]
13. Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myastenia gravis. Sun C; Meng F; Li Y; Jin Q; Li H; Li F Artif Cells Blood Substit Immobil Biotechnol; 2010 Apr; 38(2):99-102. PubMed ID: 20196680 [TBL] [Abstract][Full Text] [Related]
15. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis. Pták J Transfus Apher Sci; 2004 Apr; 30(2):125-9. PubMed ID: 15062750 [TBL] [Abstract][Full Text] [Related]
16. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536 [TBL] [Abstract][Full Text] [Related]
17. Immunoadsorption plasmapheresis for severe generalised myasthenia gravis. Ichikawa M; Koh CS; Hata Y; Tohyama M; Tsuno T; Komiyama A Arch Dis Child; 1993 Aug; 69(2):236-8. PubMed ID: 8215529 [TBL] [Abstract][Full Text] [Related]
18. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. Dau PC; Lindstrom JM; Cassel CK; Denys EH; Shev EE; Spitler LE N Engl J Med; 1977 Nov; 297(21):1134-40. PubMed ID: 917042 [TBL] [Abstract][Full Text] [Related]
19. [Myasthenia gravis: past, present and future]. Murai H Rinsho Shinkeigaku; 2014; 54(12):947-9. PubMed ID: 25672677 [TBL] [Abstract][Full Text] [Related]
20. Unravelling the pathogenesis of myasthenia gravis. Vincent A Nat Rev Immunol; 2002 Oct; 2(10):797-804. PubMed ID: 12360217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]